Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial

被引：0

作者：

Huang, W. ^{[1
]}

Han, D. ^{[1
]}

Li, B. ^{[2
]}

Dong, J. ^{[2
]}

机构：

[1] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China

[2] Shandong First Med Univ, Radiotherapy Dept, Affiliated Canc Hosp, Jinan, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1518

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1452P

引用

页码：S902 / S902

页数：1

共 50 条

[1] Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial
Han, Dan
Li, Baosheng
Huang, Wei
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial
Zhao, Wensi
Ke, Shaobo
Cai, Xiaojun
Zuo, Zhigang
Shi, Wei
Qiu, Hu
Cai, Gaoke
Gong, Yi
Wu, Yong
Ruan, Shasha
Chen, Yongshun
RADIOTHERAPY AND ONCOLOGY, 2023, 184
[3] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
Wang Feng
Qi Yu
Meng Xiangrui
Fan Qingxia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[4] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
Qiu, Tianzhu
Mingjie, Lu
Dong, Yuwen
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
[5] Preoperative camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): A single-arm, open-label, phase II study.
Yang, Hang
Zhang, Guoqing
Li, Xiangnan
Jiao, Jia
Guo, Yanan
Zhang, Yan
Hou, Zhichao
Huang, Qi
Zhao, Jia
Li, Jindong
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 360 - 360
[6] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
Chang, Zhiwei
Liu, Xiao-Lei
Yu, Dan-Dan
Han, Hui-Qiong
He, Jian
Wang, Rui-Rui
Qin, Yan-ru
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 340 - 340
[7] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
Wang Feng
Wang Junsheng
Wu Tao
Hong Yonggui
Meng Xiangrui
Ren Zhonghai
Guo Yanzhen
Yang Xiuli
Shi Pei
Yang Jiamei
Fan Qingxia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8] Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma
Luo, Huiyan
Lu, Jin
Bai, Yuxian
Mao, Teng
Wang, Jun
Fan, Qingxia
Zhang, Yiping
Zhao, Kuaile
Chen, Zhendong
Gao, Shegan
Li, Jiancheng
Fu, Zhichao
Gu, Kangsheng
Liu, Zhihua
Wu, Lin
Zhang, Xiaodong
Feng, Jifeng
Sheng, Zhen
Zeng, Wanqin
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
Wang, Feng
Qi, Yu
Meng, Xiangrui
Fan, Qingxia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
Chang, Zhiwei
Wang, Rui-Rui
Liu, Xiao-Lei
Yu, Dan-Dan
Han, Hui-Qiong
He, Jian
Qin, Yanru
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367

← 1 2 3 4 5 →